SPARKLE Trial: Crizanlizumab vs. Placebo for Frequent Vaso-Occlusive Crises in Sickle Cell Disease
Phase 3
315
about 5.5 years
12–100
13 sites in AL, DC, FL +8
What this study is about
Researchers are testing whether crizanlizumab, a treatment, is more effective than placebo at reducing the frequency of vaso-occlusive crises in adults and adolescents with sickle cell disease. The trial will last 2003 days and involve approximately 315 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Crizanlizumab
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
crizanlizumab
Secondary: Absolute change from baseline in hemoglobin, Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)